Skip to main content
. 2017 Oct 17;17:817. doi: 10.1186/s12889-017-4779-5

Table 2.

Status of drug-resistant tuberculosis in India

Drug resistance n Prevalence estimate (95% CI) Heterogeneity test (I2)
1995 to 2015
Any drug-resistance 61 42.6% (37.2; 48.0) 14.4
Multidrug resistance 73 23.3% (20.5; 26.1) 69.2
 Previously treated 37 33.7% (27.9; 39.5) 29.0
 Newly diagnosed 30 4.8% (3.7; 5.9) 79.3
Mono-drug resistance
 Isoniazid 53 7.2% (5.9; 8.4) 72.5
 Streptomycin 40 6.7% (5.4; 8.0) 67.4
 Rifampicin 42 4.6% (3.8; 5.5) 91.3
 Ethambutol 31 1.6% (1.2; 2.0) 92.0
Decade 1: 1995 to 2005
Any drug-resistance 25 37.7% (29.0; 46.4) 10.5
Multidrug resistance 24 14.9% (11.0; 18.7) 68.4
 Previously treated 13 29.8% (20.7; 39.0) 45.0
 Newly diagnosed 13 4.1% (2.7; 5.6) 70.2
Mono-drug resistance
 Isoniazid 21 8.6% (6.2; 10.9) 83.7
 Streptomycin 18 6.7% (5.0; 8.5) 81.1
 Rifampicin 15 3.6% (2.5; 4.7) 94.7
 Ethambutol 13 1.9% (1.2; 2.6) 96.1
Decade 2: 2006 to 2015
Any drug-resistance 36 46.1% (39.0; 53.2) 9.1
Multidrug resistance 49 27.9% (23.8; 32.1) 57.1
 Previously treated 24 35.8% (29.2; 42.4) 36.3
 Newly diagnosed 17 5.6% (3.8; 7.4) 82.1
Mono-drug resistance
 Streptomycin 22 6.8% (4.8; 8.8) 28.7
 Isoniazid 32 6.2% (5.0; 7.5) 24.9
 Rifampicin 27 5.1% (3.7; 6.6) 84.3
 Ethambutol 18 1.7% (1.0; 2.3) 45.2

CI Confidence interval, n Number of studies